Physician profile
Morgan E Green
NPI 1487951745
$1,660.08
in general payments reported to CMS, 2019-2025
29 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $206 · 2022: $430 · 2023: $325 · 2024: $447 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $516.64 | 2021-2025 | |
| Pfizer INC. | $165.82 | 2021-2025 | |
| Abbott Laboratories | $157.85 | 2023-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $99.35 | 2021-2025 | Ozempic |
| Glaxosmithkline, LLC. | $55.83 | 2022-2025 | Shingrix, Arexvy |
| Boston Scientific Corporation | $52.24 | 2023-2024 | |
| Amgen INC. | $44.90 | 2023-2024 | Otezla, Repatha, Krystexxa |
| Lilly USA, LLC | $43.11 | 2021-2023 | Mounjaro, Trulicity |
| Nalu Medical, INC. | $41.23 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $40.67 | 2024 | Austedo Xr |
| Dynavax Technologies Corporation | $39.80 | 2024-2025 | Heplisav-B |
| Amarin Pharma, INC. | $39.64 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.96 | 2022 | |
| Corium, LLC | $36.03 | 2023 | Azstarys |
| Inspire Medical Systems, INC. | $34.98 | 2023-2024 | Inspire |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $26.35 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $25.79 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.68 | 2024 | Trintellix |
| Xeris Pharmaceuticals, INC. | $23.93 | 2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.76 | 2022 | |
| Collegium Pharmaceutical, INC. | $17.06 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $16.84 | 2024 | |
| Organon LLC | $16.73 | 2024-2025 | Nexplanon |
| Eisai INC. | $16.22 | 2024 | |
| Janssen Pharmaceuticals, INC | $14.38 | 2024 | Spravato |
| Kowa Pharmaceuticals America, INC. | $14.25 | 2023 | Livalo, Seglentis |
| Ibsa Pharma INC. | $13.75 | 2022 | |
| Halozyme INC | $13.29 | 2023 | |
| Mannkind Corporation | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.